FLKS Flex Pharma Inc.

3.44
-0.16  -4%
Previous Close 3.60
Open 3.65
Price To book 1.39
Market Cap 61823047
Shares 17,971,816
Volume 56,293
Short Ratio 7.43
Av. Daily Volume 136,162

SEC filingsSee all SEC filings

  1. 8-K - Current report 171055098
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000016
  3. 8-K - Current report 17998394
  4. 8-K - Current report 17959709
  5. 8-K - Current report 17893141

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 start noted August 1, 2017. Data due mid-2018.
FLX-787 - COMMEND US trial
Amyotrophic lateral sclerosis (ALS)
Phase 2 trial to commence 3Q 2017.
FLX-787
Charcot-Marie-Tooth (CMT)
Phase 2 endpoints not met - October 2016. Announced January 24, 2017 that other indications will take priority over nocturnal leg cramps.
FLX-787
Nocturnal Leg Cramp
Phase 2 data due by the end of 2017.
FLX-787
Multiple Sclerosis
Phase 2 initiated September 2016. Readout due 2017/18.
FLX-787
Amyotrophic lateral sclerosis (ALS)

Latest News

  1. Flex Pharma Presenting at Upcoming Investor Conferences in September 2017
  2. ETFs with exposure to Flex Pharma, Inc. : September 1, 2017
  3. Flex Pharma, Inc. :FLKS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  4. Edited Transcript of FLKS earnings conference call or presentation 2-Aug-17 12:45pm GMT
  5. Flex Pharma reports 2Q loss
  6. Flex Pharma Reports Second Quarter 2017 Financial Results
  7. Investor Network: Flex Pharma, Inc. to Host Earnings Call
  8. Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
  9. Flex Pharma Names William McVicar President and Chief Executive Officer
  10. Corporate News Blog - FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
  11. Today's Research Reports on Stocks to Watch: Neuralstem and Flex Pharma
  12. Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017
  13. FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
  14. Flex Pharma Announces Executive Leadership Transition
  15. Flex Pharma’s Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium
  16. Flex Pharma Presenting at Upcoming Investor Conferences in June 2017
  17. Edited Transcript of FLKS earnings conference call or presentation 3-May-17 12:45pm GMT
  18. Flex Pharma Reports First Quarter 2017 Financial Results
  19. FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND

SEC Filings

  1. 8-K - Current report 171055098
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000016
  3. 8-K - Current report 17998394
  4. 8-K - Current report 17959709
  5. 8-K - Current report 17893141
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 17809885
  7. 8-K - Current report 17807227
  8. DEF 14A - Other definitive proxy statements 17770145
  9. 8-K - Current report 17742348
  10. S-8 - Securities to be offered to employees in employee benefit plans 17675371